{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:35:04Z","timestamp":1793745304887,"version":"4.6.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41591-024-03458-w","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T10:08:54Z","timestamp":1736330934000},"page":"1130-1133","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["T cell malignancies after CAR T\u2009cell therapy in the DESCAR-T registry"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5024-1713","authenticated-orcid":false,"given":"Remy","family":"Dulery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4301-3771","authenticated-orcid":false,"given":"Vincent","family":"Guiraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7791-0470","authenticated-orcid":false,"given":"Sylvain","family":"Choquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9941-2448","authenticated-orcid":false,"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2694-7510","authenticated-orcid":false,"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1593-9750","authenticated-orcid":false,"given":"St\u00e9phane","family":"Barete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9260-8616","authenticated-orcid":false,"given":"\u00c8ve","family":"Todesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Arnulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2091-7927","authenticated-orcid":false,"given":"Nicolas","family":"Boissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7032-5180","authenticated-orcid":false,"given":"Jacques-Olivier","family":"Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-8213","authenticated-orcid":false,"given":"Roch","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"3458_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(23)00631-9","volume":"25","author":"B Furlow","year":"2024","unstructured":"Furlow, B. FDA investigates risk of secondary lymphomas after CAR-T immunotherapy. Lancet Oncol. 25, 21 (2024).","journal-title":"Lancet Oncol."},{"key":"3458_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMp2400209","volume":"390","author":"N Verdun","year":"2024","unstructured":"Verdun, N. & Marks, P. Secondary cancers after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 390, 584\u2013586 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3458_CR3","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1182\/blood-2023-178806","volume":"142","author":"SJ Harrison","year":"2023","unstructured":"Harrison, S. J. et al. CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma. Blood 142, 6939 (2023).","journal-title":"Blood"},{"key":"3458_CR4","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi, G. et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat. Med. 30, 984\u2013989 (2024).","journal-title":"Nat. Med."},{"key":"3458_CR5","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","volume":"390","author":"M Ozdemirli","year":"2024","unstructured":"Ozdemirli, M. et al. Indolent CD4+ CAR T-cell lymphoma after cilta-cel CAR T-cell therapy. N. Engl. J. Med. 390, 2074\u20132082 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3458_CR6","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton, M. P. et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N. Engl. J. Med. 390, 2047\u20132060 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3458_CR7","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1182\/blood.2024024166","volume":"143","author":"M Elsallab","year":"2024","unstructured":"Elsallab, M. et al. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System. Blood 143, 2099\u20132105 (2024).","journal-title":"Blood"},{"key":"3458_CR8","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1001\/jamaoncol.2024.0662","volume":"10","author":"R Storgard","year":"2024","unstructured":"Storgard, R., Rejeski, K., Perales, M. A., Goldman, A. & Shouval, R. T-cell malignant neoplasms after chimeric antigen receptor T-cell therapy. JAMA Oncol. 10, 826\u2013828 (2024).","journal-title":"JAMA Oncol."},{"key":"3458_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cell.2021.12.011","volume":"185","author":"KB Einkauf","year":"2022","unstructured":"Einkauf, K. B. et al. Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses. Cell 185, 266\u2013282.e15 (2022).","journal-title":"Cell"},{"key":"3458_CR10","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1126\/science.1256304","volume":"345","author":"TA Wagner","year":"2014","unstructured":"Wagner, T. A. et al. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345, 570\u2013573 (2014).","journal-title":"Science"},{"key":"3458_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24080-1","volume":"12","author":"B Cole","year":"2021","unstructured":"Cole, B. et al. In-depth single-cell analysis of translation-competent HIV-1 reservoirs identifies cellular sources of plasma viremia. Nat. Commun. 12, 3727 (2021).","journal-title":"Nat. Commun."},{"key":"3458_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1107239","volume":"14","author":"JY Zhao","year":"2023","unstructured":"Zhao, J. Y. et al. Phospholipase A and acyltransferase 4\/retinoic acid receptor responder 3 at the intersection of tumor suppression and pathogen restriction. Front Immunol. 14, 1107239 (2023).","journal-title":"Front Immunol."},{"key":"3458_CR13","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/sj.leu.2402243","volume":"15","author":"B Casanova","year":"2001","unstructured":"Casanova, B. et al. The class II tumor-suppressor gene RARRES3 is expressed in B cell lymphocytic leukemias and down-regulated with disease progression. Leukemia 15, 1521\u20131526 (2001).","journal-title":"Leukemia"},{"key":"3458_CR14","doi-asserted-by":"publisher","first-page":"101847","DOI":"10.18632\/oncotarget.21988","volume":"8","author":"N Mustafa","year":"2017","unstructured":"Mustafa, N. et al. VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim. Oncotarget 8, 101847\u2013101864 (2017).","journal-title":"Oncotarget"},{"key":"3458_CR15","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.cellsig.2006.11.005","volume":"19","author":"FM Tsai","year":"2007","unstructured":"Tsai, F. M., Shyu, R. Y. & Jiang, S. Y. RIG1 suppresses Ras activation and induces cellular apoptosis at the Golgi apparatus. Cell Signal. 19, 989\u2013999 (2007).","journal-title":"Cell Signal."},{"key":"3458_CR16","doi-asserted-by":"publisher","first-page":"23790","DOI":"10.1074\/jbc.M112.361550","volume":"287","author":"M Golczak","year":"2012","unstructured":"Golczak, M. et al. Structural basis for the acyltransferase activity of lecithin:retinol acyltransferase-like proteins. J. Biol. Chem. 287, 23790\u201323807 (2012).","journal-title":"J. Biol. Chem."},{"key":"3458_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307\u2013312 (2018).","journal-title":"Nature"},{"key":"3458_CR18","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","volume":"5","author":"PG Miller","year":"2021","unstructured":"Miller, P. G. et al. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 5, 2982\u20132986 (2021).","journal-title":"Blood Adv."},{"key":"3458_CR19","doi-asserted-by":"publisher","first-page":"e957","DOI":"10.1097\/HS9.0000000000000957","volume":"7","author":"V Panagiota","year":"2023","unstructured":"Panagiota, V. et al. Clinical implications and dynamics of clonal hematopoiesis in anti-CD19 CAR T-cell treated patients. HemaSphere 7, e957 (2023).","journal-title":"HemaSphere"},{"key":"3458_CR20","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1182\/bloodadvances.2021005747","volume":"6","author":"R Teipel","year":"2022","unstructured":"Teipel, R. et al. Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Adv. 6, 1941\u20131946 (2022).","journal-title":"Blood Adv."},{"key":"3458_CR21","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine, B. L. et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat. Med. 30, 338\u2013341 (2024).","journal-title":"Nat. Med."},{"key":"3458_CR22","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1200\/JCO.2008.21.1920","volume":"27","author":"AT Meadows","year":"2009","unstructured":"Meadows, A. T. et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J. Clin. Oncol. 27, 2356\u20132362 (2009).","journal-title":"J. Clin. Oncol."},{"key":"3458_CR23","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","volume":"373","author":"M Schaapveld","year":"2015","unstructured":"Schaapveld, M. et al. Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma. N. Engl. J. Med. 373, 2499\u20132511 (2015).","journal-title":"N. Engl. J. Med."},{"key":"3458_CR24","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1200\/JCO.21.02372","volume":"40","author":"S Bhatia","year":"2022","unstructured":"Bhatia, S. et al. Trends in late mortality and life expectancy after autologous blood or marrow transplantation over three decades: a BMTSS report. J. Clin. Oncol. 40, 1991\u20132003 (2022).","journal-title":"J. Clin. Oncol."}],"updated-by":[{"DOI":"10.1038\/s41591-025-03717-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03458-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03458-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03458-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T06:01:02Z","timestamp":1745647262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03458-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3458"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03458-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"11 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-025-03717-4","URL":"https:\/\/doi.org\/10.1038\/s41591-025-03717-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.D. reports research funding from Ligue Contre le Cancer, Arthur Sachs Scholarship Fund, Monahan Foundation, Servier Foundation, Philippe Foundation and DCP AP-HP; honoraria from Novartis and Takeda; and support for attending meetings and\/or travel from Sanofi and Kite Pharma\/Gilead. S.C. reports personal fees from Kite Pharma\/Gilead, Novartis, Janssen, Celgene-BMS, Takeda, Atara, Astra Zeneca, Pierre Fabre, Viatris and Lilly. C.T. reports membership on an entity\u2019s Board of Directors or advisory committees of Kite Pharma\/Gilead, Amgen, AbbVie, Novartis, Roche, Gilead Sciences, Takeda, BMS\/Celgene, Incyte and Cellectis; consultancy for Kite Pharma\/Gilead, Amgen, AbbVie, Novartis, Gilead Sciences, Cellectis, Roche and BMS\/Celgene; honoraria from Takeda, Incyte, Bayer, Kite Pharma\/Gilead, Novartis, BMS, Abbvie, F. Hoffmann-La Roche Ltd., Amgen, Cellectis and Janssen; research funding from Hospira and BMS\/Celgene; and support for attending meetings and\/or travel from Kite Pharma\/Gilead, Amgen, AbbVie, Novartis, Gilead Sciences, Cellectis, Roche, BMS\/Celgene and Janssen. E.B. reports participation on a data safety monitoring board or advisory board of Novartis, Kite Pharma\/Gilead, Roch, Incyte, ADC Therapeutics, Abbvie and Beigene; consultancy for Kite Pharma\/Gilead, Amgen, AbbVie, Novartis, Gilead Sciences, Cellectis, Roche and BMS\/Celgene; honoraria from Novartis, Kite Pharma\/Gilead, Roche, Takeda, Janssen, Abbvie and Astra Zeneca; research funding from Amgen and BMS; and support for attending meetings and\/or travel from Roche, Kite Pharma\/Gilead and Novartis. R.H. reports honoraria from Kite Pharma\/Gilead, Novartis, Incyte, Janssen, MSD, Takeda, Amgen, Abbvie and Roche; and membership on an entity\u2019s Board of Directors or advisory committees of Kite Pharma\/Gilead, Novartis, Bristol-Myers Squibb\/Celgene, Incyte, Roche and Miltenyi. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}